Anivive Sponsors 69th Annual Coccidioidomycosis Study Group Meeting

• Hosted by Arizona State University and Mayo Clinic
• Anivive provides $50,000 in travel awards
• Leading global experts pioneering novel fungal vaccines, therapeutics and diagnostics

LONG BEACH, Calif., Feb. 27, 2025 /PRNewswire/ — Anivive, a software-driven pet health company, announces their sponsorship of the 69^th Annual Coccidioidomycosis Study Group on April 4-5, 2025 hosted by Arizona State University and Mayo Clinic at the ASU Health Futures Center in Phoenix, AZ.

In additional to financial support for the meeting, Anivive is providing $50,000 in Travel Awards to cover airfare and lodging for up to 25 eligible Study Group attendees.

Since 2017, Anivive has partnered with the Valley Fever Center for Excellence at the University of Arizona, to advance their live-vaccine candidate through preclinical and clinical studies for veterinary use. In August 2024, Anivive secured a $33 million contract from the National Institute of Allergy and Infectious Diseases, to support adapting their canine vaccine for human use, with the potential to be the world’s first vaccine against a systemic fungal infection.

“Anivive is proud to provide ongoing support to these world-renowned experts in fungal disease,” said Dylan Balsz, Anivive CEO. “Our dedication extends beyond this initiative—we have made significant progress with our Valley fever program and this meeting brings together many of our partners to tackle the challenges faced in bringing fungal vaccines, therapeutics and diagnostics to market.”

To learn more about Anivive’s Valley Fever vaccine visit https://www.anivive.com/valley-fever

About Anivive Lifesciences

Anivive Lifesciences is a software-driven pet pharmaceutical company at the forefront of biotechnology, artificial intelligence, and veterinary medicine. Our mission is to transform veterinary healthcare by accelerating the development of novel, affordable treatments for life-threatening diseases in pets. Through our proprietary AI platform, we are pioneering first-in-class therapeutics in Oncology, Antivirals, and Antifungal Vaccines, setting new standards for innovation and excellence in the industry. To learn more, visit anivive.com 

About Coccidioidomycosis Study Group

The Coccidioidomycosis Study Group was created in San Francisco, California on July 18, 1956. This group oversees conferences, annual meetings and research studies. Much of the documented knowledge of the pathogenesis, mycology and clinical aspects of Coccidioidomycosis originated from studies performed by this research group. To learn more, visit https://coccistudygroup.org/

View original content to download multimedia:https://www.prnewswire.com/news-releases/anivive-sponsors-69th-annual-coccidioidomycosis-study-group-meeting-302387534.html

SOURCE Anivive Lifesciences Inc.